EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Immunotherapy Targeting PD-1/PD-L1 in Early-Stage Triple-Negative Breast Cancer

Tinglin Yang iD, Wenhui Li iD, Tao Huang iD, Jun Zhou

Journal of Personalized Medicine · 15.03.2023 · 13 (3) · 526

DOI: 10.3390/jpm13030526 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Personalized Medicine, online erschienen am 15.03.2023. Verfasst von Tinglin Yang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 109 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The advent of immunotherapy, especially immune checkpoint inhibitors (ICIs), has revolutionized antitumor therapy. Programmed cell death receptor 1 (PD-1) and programmed cell death ligand 1 (PD-L1) are among the most promising targets for encouraging the immune system to eliminate cancer cells. PD-1/PD-L1 have made clinical remission for numerous solid tumors, including metastatic triple-negative breast cancer (TNBC). In recent years, integrating PD-1/PD-L1 inhibitors into existing treatments in early-stage TNBC has attracted wide attention. Herein, we summarize the clinical benefit of PD-1/PD-L1 inhibitors plus neoadjuvant chemotherapy, adjuvant chemotherapy, and targeted therapy in early-stage TNBC. Possible immunotherapy biomarkers, immune-related adverse events (irAEs), and the key challenges faced in TNBC anti-PD-1/PD-L1 therapy are also concluded. Numerous studies on immunotherapy are ongoing, and PD-1/PD-L1 inhibitors have demonstrated great clinical prospects in early-stage TNBC. To maximize the efficacy of anti-PD-1/PD-L1 therapy, further research into the challenges which still exist is necessary.

Schlagwörter

Stichwörter der Autor:innen

PD-1/PD-L1early-stage breast cancerimmunotherapyirAEstriple-negative breast cancer

Autor:innen und Institutionen

  • Department of Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.

ORCID-Profile: Tinglin Yang, Wenhui Li, Tao Huang

Zitieren

APA

Yang, T., Li, W., Huang, T., & Zhou, J. (2023). Immunotherapy Targeting PD-1/PD-L1 in Early-Stage Triple-Negative Breast Cancer. Journal of Personalized Medicine, 13(3), 526. https://doi.org/10.3390/jpm13030526

Vancouver

Yang T, Li W, Huang T, Zhou J. Immunotherapy Targeting PD-1/PD-L1 in Early-Stage Triple-Negative Breast Cancer. Journal of Personalized Medicine. 2023;13(3):526. doi:10.3390/jpm13030526

BibTeX
@article{Yang2023,
  author = {Yang, Tinglin and Li, Wenhui and Huang, Tao and Zhou, Jun},
  title = {Immunotherapy Targeting PD-1/PD-L1 in Early-Stage Triple-Negative Breast Cancer},
  journal = {Journal of Personalized Medicine},
  year = {2023},
  volume = {13},
  number = {3},
  pages = {526},
  doi = {10.3390/jpm13030526}
}
Kostenlos starten →